E
Evarist Feliu
Researcher at Autonomous University of Barcelona
Publications - 144
Citations - 3317
Evarist Feliu is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Lymphoma & Transplantation. The author has an hindex of 28, co-authored 144 publications receiving 2942 citations. Previous affiliations of Evarist Feliu include University of Barcelona & University of Paris.
Papers
More filters
Journal ArticleDOI
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
Albert Oriol,Susana Vives,Jesús María Hernández-Rivas,Mar Tormo,Inmaculada Heras,Concepción Rivas,Concepción Bethencourt,Federico Moscardó,Javier Bueno,Carlos Grande,Eloy del Potro,Ramon Guardia,Salut Brunet,Juan Bergua,Teresa Bernal,María-José Moreno,Carlota Calvo,Pilar Bastida,Evarist Feliu,Josep-Maria Ribera +19 more
TL;DR: The prognosis of adult patients with acute lymphoblastic leukemia who relapse is poor; those aged less than 30 years with a first complete remission lasting longer than 2 years have reasonable possibilities of becoming long-term survivors while patients over this age or those who relapse early cannot be successfully rescued using the therapies currently available.
Journal ArticleDOI
Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.
TL;DR: Current therapeutic procedures may be considered as quite satisfactory in patients with polycythemia vera and essential thrombocythemia, and due to poor survival of patients with idiopathic myelofibrosis, new therapeutic approaches for this condition are clearly needed.
Journal ArticleDOI
Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96
Josep-Maria Ribera,Albert Oriol,Miguel-Angel Sanz,Mar Tormo,Pascual Fernández-Abellán,Eloy del Potro,Eugenia Abella,Javier Bueno,Ricardo Parody,Pilar Bastida,Carlos Grande,Inmaculada Heras,Concepción Bethencourt,Evarist Feliu,J. J. Ortega +14 more
TL;DR: The response to the pediatric ALL-96 protocol was identical in adolescents and young adults despite a slight increase in hematologic toxicity observed in adults, which justifies the age-unrestricted use of pediatric regimens to treat patients with SR ALL.
Journal ArticleDOI
Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
Josep-Maria Ribera,Albert Oriol,Mireia Morgades,Pau Montesinos,Josep Sarrá,José González-Campos,Salut Brunet,Mar Tormo,Pascual Fernández-Abellán,Ramon Guardia,Maria-Teresa Bernal,Jordi Esteve,Pere Barba,María-José Moreno,Arancha Bermúdez,Antonia Cladera,Lourdes Escoda,Raimundo García-Boyero,Eloy del Potro,Juan Bergua,María-Luz Amigo,Carlos Grande,Maria-Jose Rabuñal,Jesús María Hernández-Rivas,Evarist Feliu +24 more
TL;DR: Prognosis for Ph-negative HR-ALL in adolescents and adults with good early response to induction and low flow-MRD levels after consolidation is quite favorable when allo-HSCT is avoided.
Journal ArticleDOI
Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
José-Tomás Navarro,Josep-Maria Ribera,Albert Oriol,Vaquero M,Joan Romeu,Montserrat Batlle,Flores A,Fuensanta Millá,Evarist Feliu +8 more
TL;DR: HAART was an independent prognostic factor for CR, OS and EFS in patients with AIDS‐related NHL treated with CHOP and HAART had a higher CR rate than those treated only withCHOP.